Clinical trial

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-08-08

PhasePHASE1

Study timeline

Study start (actual)2023-08-08Date precision: day

Registry last updated2026-09-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Esophageal Cancerunresolved

Small Cell Lung Cancerunresolved

Nasopharyngeal Cancerunresolved

Head and Neck Squamous Cell Carcinomaunresolved

Prostate Adenocarcinomaunresolved

Ovarian Cancerunresolved

Endometrial Cancerunresolved

Cervical Cancerunresolved

Triple Negative Breast Cancerunresolved

Interventions

Sponsors & collaborators

SystImmune Inc.lead sponsor

Mapped research locations

MadridSpain4 HoustonTexas, United States2 BostonMassachusetts, United States2 BarcelonaSpain2 New YorkNew York, United States1 ChicagoIllinois, United States1 MiamiFlorida, United States1 NashvilleTennessee, United States1 SeattleWashington, United States1 ParisFrance1 Washington D.C.District of Columbia, United States1 OrlandoFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05983432 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.